tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
David Risinger

David Risinger

SVB Securities
Wall Street Analyst
Ranked #4,893 out of 8,019 Analysts on TipRanks (#12,125 out of 21,482 overall experts)

Success Rate

38%
10 out of 26 Profitable Transactions

Average Return

0.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied David Risinger's ratings since 2022 and opened each position for the duration of 1 Year:
38.46% of your transactions would have been profitable with an average return of 0.5%

Stock Rating Distribution

57Ratings
49.12% Buy
43.86% Hold
7.02% Sell
Distribution of David Risinger's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Prometheus Biosciences, Inc
(RXDX)
Rating Type:Buy
Dates:Jul 18, 2022 - Jan 01, 1970
Gain:60.80%
The most profitable rating made by David Risinger

David Risinger's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Roivant Sciences
Buy
Reiterated
$7.00
(60.18% Upside)
50%
+1.80%
2
Prometheus Biosciences
Buy
Reiterated
100%
+60.80%
1
HilleVax, Inc
Buy
Reiterated
50%
+9.75%
2
Pfizer
Hold
Assigned
$53.00
(5.79% Upside)
0.00%
6
AbbVie
Sell
Reiterated
$140.00
(-1.80% Downside)
67%
+2.57%
4
Gilead Sciences
Hold
Reiterated
$68.00
(8.01% Upside)
0.00%
2
Vertex Pharmaceuticals
Hold
Reiterated
$265.00
(-10.02% Downside)
0.00%
5
Eli Lilly & Co
Buy
Assigned
$341.00
(10.79% Upside)
25%
-4.05%
6
Regeneron
Hold
Reiterated
$630.00
(0.21% Upside)
0%
-12.70%
4
Horizon Therapeutics
Buy
Upgraded
$80.00
(18.57% Upside)
100%
+0.10%
2
List of latest recommendations made by David Risinger. Click to expand and see David Risinger's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More